PD02 A Literature Review Of Treatment Schemes And Effects For Beta Thalassemia In China

Introduction The incidence of beta thalassemia varies greatly in different regions China. Blood transfusion combined with iron chelation and hematopoietic stem cell transplantation (HSCT) is the main treatment for This study aimed to reveal specific schemes used patients evaluate their effects. Methods A search strategy was developed identify articles published between 1 January 2010 30 August 2021 following literature databases: PubMed, Embase, China National Knowledge Infrastructure, Wanfang Data, Chinese BioMedical Literature Database. Results most included deferoxamine (DFO) monotherapy, deferiprone (DFP) deferasirox (DFX) combinations DFP DFO. Most studies reported that DFP, DFO, DFX monotherapy performed better than DFO or alone reducing blood, heart, liver load. However, adverse effects affected patient compliance a certain extent. Stem cells receiving HSCT were mainly donated by human leukocyte antigen (HLA)-matched siblings unrelated individuals. five-year overall survival rate after ranged from 83 90 percent, while thalassemia-free 65 87 percent. Graft-versus-host disease infection common serious complications experienced transplant recipients. Conclusions For thalassemia, effective monotherapy. HLA-matched donors resulted significant improvement cure thalassemia. still need safer more innovative treatments, further evidence on existing treatments needs be generated larger scale population.